I did my undergraduate Mchem degree at Durham, where I spent my master's year working on the development of new gram-negative antibiotics as part of an industrial placement at Roche, Switzerland. During my degree, I completed a Laidlaw research scholarship working on the enantioselective synthesis of chiral quaternary ammoniums.

In 2020, I joined the Gaunt group in Cambridge as part of the SynTech CDT, where my work centres on the carbonyl alkylative amination array synthesis of complex amines using a high throughput platform. This research aims to achieve: directed screening for reaction scope broadening; generation of high-quality, standardised datasets for machine learning applications (such as predictive modelling); tandem library synthesis and bioassay for the discovery of new lead compounds for drug discovery.

I joined SynTech as its core values and research focus align with my beliefs about the future of synthetic chemistry. Whilst traditional flask chemistry has brought us many amazing discoveries and will continue to do so; leveraging modern technology will help accelerate discovery. The number of potential synthesisable molecules and the demand for new chemicals, such as drug molecules, increases every day. Automation and machine learning offer us synergistic opportunities for the creation of large, focused libraries of compounds for generating essential data. My experience in drug discovery has shown me the need for new disruptive technologies to change the way we approach the search for new therapeutics. As an organic chemist, I am excited to approach the synthetic challenges associated with transferring traditional chemistry into new technology workflows.